STOCK TITAN

RCM Technologies, Inc. Announces First Quarter Results

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)
Tags
RCM Technologies (RCMT) reported strong Q1 2025 financial results, with revenue reaching $84.5 million, up 17.4% from $71.9 million in Q1 2024. The company's GAAP net income increased to $4.2 million ($0.54 per diluted share) compared to $4.0 million ($0.48 per diluted share) in the prior year. Adjusted EBITDA rose to $7.8 million from $6.8 million. Notable achievements include generating $16.7 million in operating cash flow and reducing net debt by $12.0 million while continuing share repurchases. The Specialty Healthcare segment led revenue generation with $43.3 million, followed by Engineering at $32.1 million, and Life Sciences at $9.0 million. The company's gross profit margin was 26.0%, with Life Sciences achieving the highest segment margin at 39.7%.
RCM Technologies (RCMT) ha riportato solidi risultati finanziari del primo trimestre 2025, con ricavi pari a 84,5 milioni di dollari, in aumento del 17,4% rispetto ai 71,9 milioni di dollari del primo trimestre 2024. L'utile netto GAAP è salito a 4,2 milioni di dollari (0,54 dollari per azione diluita) rispetto ai 4,0 milioni di dollari (0,48 dollari per azione diluita) dell'anno precedente. L'EBITDA rettificato è aumentato a 7,8 milioni di dollari dai 6,8 milioni precedenti. Tra i risultati più rilevanti si segnalano un flusso di cassa operativo di 16,7 milioni di dollari e una riduzione del debito netto di 12,0 milioni di dollari, mantenendo al contempo il riacquisto di azioni. Il segmento Specialty Healthcare ha guidato la generazione di ricavi con 43,3 milioni di dollari, seguito da Engineering con 32,1 milioni di dollari e Life Sciences con 9,0 milioni di dollari. Il margine lordo dell'azienda è stato del 26,0%, con Life Sciences che ha registrato il margine segmentale più elevato, pari al 39,7%.
RCM Technologies (RCMT) reportó sólidos resultados financieros del primer trimestre de 2025, con ingresos que alcanzaron 84,5 millones de dólares, un aumento del 17,4% respecto a los 71,9 millones de dólares del primer trimestre de 2024. El ingreso neto GAAP aumentó a 4,2 millones de dólares (0,54 dólares por acción diluida) frente a los 4,0 millones de dólares (0,48 dólares por acción diluida) del año anterior. El EBITDA ajustado subió a 7,8 millones de dólares desde 6,8 millones. Entre los logros destacados se incluyen generar 16,7 millones de dólares en flujo de caja operativo y reducir la deuda neta en 12,0 millones de dólares mientras se continuaban las recompras de acciones. El segmento de Specialty Healthcare lideró la generación de ingresos con 43,3 millones de dólares, seguido por Engineering con 32,1 millones y Life Sciences con 9,0 millones. El margen bruto de la compañía fue del 26,0%, con Life Sciences alcanzando el margen segmental más alto, del 39,7%.
RCM Technologies(RCMT)는 2025년 1분기 재무 실적을 강하게 보고했으며, 매출은 8,450만 달러로 2024년 1분기 7,190만 달러 대비 17.4% 증가했습니다. 회사의 GAAP 순이익은 420만 달러(희석 주당 0.54달러)로 전년 동기 400만 달러(희석 주당 0.48달러) 대비 증가했습니다. 조정 EBITDA는 780만 달러로 680만 달러에서 상승했습니다. 주요 성과로는 1,670만 달러의 영업 현금 흐름 창출과 순부채를 1,200만 달러 줄이면서 주식 재매입을 지속한 점이 있습니다. Specialty Healthcare 부문이 4,330만 달러의 매출을 이끌었고, Engineering 부문이 3,210만 달러, Life Sciences 부문이 900만 달러를 기록했습니다. 회사의 총이익률은 26.0%였으며, Life Sciences 부문이 39.7%로 가장 높은 부문별 마진을 달성했습니다.
RCM Technologies (RCMT) a annoncé de solides résultats financiers pour le premier trimestre 2025, avec un chiffre d'affaires atteignant 84,5 millions de dollars, en hausse de 17,4 % par rapport à 71,9 millions de dollars au premier trimestre 2024. Le résultat net GAAP a augmenté pour atteindre 4,2 millions de dollars (0,54 dollar par action diluée) contre 4,0 millions de dollars (0,48 dollar par action diluée) l'année précédente. L'EBITDA ajusté est passé à 7,8 millions de dollars contre 6,8 millions. Parmi les réalisations notables figurent la génération de 16,7 millions de dollars de flux de trésorerie opérationnel et la réduction de la dette nette de 12,0 millions de dollars, tout en poursuivant les rachats d'actions. Le segment Specialty Healthcare a mené la génération de revenus avec 43,3 millions de dollars, suivi par Engineering avec 32,1 millions et Life Sciences avec 9,0 millions. La marge brute de l'entreprise s'est établie à 26,0 %, avec Life Sciences affichant la marge segmentaire la plus élevée à 39,7 %.
RCM Technologies (RCMT) meldete starke Finanzergebnisse für das erste Quartal 2025 mit einem Umsatz von 84,5 Millionen US-Dollar, was einem Anstieg von 17,4 % gegenüber 71,9 Millionen US-Dollar im ersten Quartal 2024 entspricht. Der GAAP-Nettogewinn stieg auf 4,2 Millionen US-Dollar (0,54 US-Dollar pro verwässerter Aktie) im Vergleich zu 4,0 Millionen US-Dollar (0,48 US-Dollar pro verwässerter Aktie) im Vorjahr. Das bereinigte EBITDA stieg von 6,8 Millionen auf 7,8 Millionen US-Dollar. Zu den bemerkenswerten Leistungen zählen die Generierung von 16,7 Millionen US-Dollar operativem Cashflow und die Reduzierung der Nettoverschuldung um 12,0 Millionen US-Dollar, während weiterhin Aktienrückkäufe durchgeführt wurden. Das Segment Specialty Healthcare führte mit 43,3 Millionen US-Dollar den Umsatz an, gefolgt von Engineering mit 32,1 Millionen US-Dollar und Life Sciences mit 9,0 Millionen US-Dollar. Die Bruttogewinnmarge des Unternehmens lag bei 26,0 %, wobei Life Sciences mit 39,7 % die höchste Segmentmarge erzielte.
Positive
  • Revenue increased 17.4% YoY to $84.5 million
  • Operating cash flow of $16.7 million
  • Net debt reduced by $12.0 million
  • Adjusted EBITDA grew to $7.8 million from $6.8 million YoY
  • Adjusted EPS increased to $0.63 from $0.53 YoY
Negative
  • Gross profit margin declined to 26.0% from 28.3% YoY
  • Engineering segment gross margin decreased to 19.2% from 23.4% YoY
  • Life Sciences revenue decreased to $9.0 million from $10.2 million YoY

Insights

RCM posted strong Q1 with 17.4% revenue growth and excellent cash flow, though margins compressed as Engineering surged and Life Sciences declined.

RCM Technologies delivered impressive revenue growth of 17.4% in Q1 2025, reaching $84.5 million compared to $71.9 million in the prior year period. This double-digit growth demonstrates significant momentum in their business expansion strategy.

The company's profitability metrics showed mixed results. Gross profit increased 7.9% to $22.0 million, but gross margin compressed from 28.3% to 26.0%. This margin pressure was most pronounced in the Engineering segment, which saw margins decrease from 23.4% to 19.2% despite posting the strongest revenue growth of 36.7% year-over-year.

Net income grew modestly to $4.2 million ($0.54 per diluted share) from $4.0 million ($0.48 per diluted share) in the comparable quarter. The adjusted metrics showed more substantial improvement, with adjusted EBITDA increasing to $7.8 million from $6.8 million and adjusted EPS rising to $0.63 from $0.53.

Segment performance varied significantly across the business:

  • Engineering: Revenue surged 36.7% to $32.1 million, though with compressed margins
  • Specialty Health Care: Revenue increased 13.4% to $43.3 million with a slight margin decline
  • Life Sciences, Data and Solutions: Revenue declined 11.7% to $9.0 million, though margins improved to 39.7%

The standout aspect of the quarter was exceptional cash flow generation, with $16.7 million from operations - nearly four times the reported net income. This robust cash conversion allowed RCM to significantly strengthen its balance sheet by reducing net debt by $12.0 million while simultaneously funding $4.1 million in share repurchases and retirements.

The ongoing share repurchase program has reduced diluted share count by 5.3% year-over-year, which management highlighted as enhancing "the compounding of returns to the benefit of shareholders." With accounts receivable decreasing despite higher revenue, the company appears to be improving working capital efficiency while maintaining its growth trajectory.

PENNSAUKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- RCM Technologies, Inc. (NasdaqGM: RCMT), a premier provider of solutions designed to enhance the operational performance of its customers through the deployment of advanced engineering, specialty health care, and information technology services, today announced financial results for the thirteen weeks ended March 29, 2025.

RCM Technologies reported revenue of $84.5 million for the thirteen weeks ended March 29, 2025 (the current quarter), an increase of 17.4% compared to $71.9 million for the thirteen weeks ended March 30, 2024 (the comparable prior quarter). Gross profit was $22.0 million for the current quarter, a 7.9% increase compared to $20.4 million for the comparable prior quarter.  The Company experienced GAAP net income of $4.2 million, or $0.54 per diluted share, for the current quarter compared to $4.0 million, or $0.48 per diluted share, for the comparable prior quarter. The Company experienced adjusted EBITDA (non-GAAP) of $7.8 million for the current quarter, as compared to $6.8 million for the comparable prior quarter. The Company experienced $0.63 of adjusted net income per diluted share (non-GAAP) for the current quarter as compared to $0.53 for the comparable prior quarter.

Bradley Vizi, Executive Chairman of RCM Technologies, commented, “The internals of our business continue to strengthen at an increasing rate. We believe the company is well positioned based on the thoughtful investment strategy we have deployed, and significant reductions in our share count should enhance the compounding of returns to the benefit of shareholders.”

Kevin Miller, Chief Financial Officer of RCM Technologies, commented, “We are very pleased with our cash flow this quarter, as we generated $16.7 million in cash flow from operations and reduced our net debt by $12.0 million while retiring shares and growing earnings at a healthy clip.”

Conference Call
On Thursday, May 8, 2025, RCM Technologies will host a conference call to discuss these results. The call will begin at 10:30 a.m. Eastern Time. The dial-in number is (888) 272-8703.

About RCM
RCM Technologies (NasdaqGM: RCMT) is a business and technology solutions provider with world-class talent in key market segments. We help design, build, and enable the Industries of Tomorrow, Today. Operating at the intersection of resources, critical infrastructure and modernization of industries, RCM is a provider of services in Health Care, Engineering, Aerospace & Defense, Process & Industrial, Life Sciences and Data & Solutions. www.rcmt.com.

The statements contained in this release that are not purely historical are forward-looking statements within the Private Securities Litigation Reform Act of 1995. They are subject to various risks, uncertainties, and other factors that could cause the Company’s actual results, performance, or achievements to differ materially from those expressed or implied by such forward-looking statements. These statements often include words such as “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “believe,” “plan,” “seek,” “could,” “can,” “should,” “are confident” or similar expressions. In addition, statements that are not historical should also be considered forward-looking statements. These statements are based on assumptions that we have made in light of our experience in the industry, and our perceptions of historical trends, current conditions, expected future developments, and other factors we believe are appropriate in these circumstances. Forward-looking statements include, but are not limited to, those relating to demand for the Company’s services, expectations regarding our future revenues and other financial results, such as cash flows, our pipeline, and potential project wins, and our expectations for investment and growth in our business. Such statements are based on current expectations that involve several known and unknown risks, uncertainties, and other factors, which may cause actual events to be materially different from those expressed or implied by such forward-looking statements. Risk, uncertainties, and other factors may emerge from time to time that could cause the Company’s actual results to differ from those indicated by the forward-looking statements. Investors are directed to consider such risks, uncertainties, and other factors described in documents filed by the Company with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company assumes no obligation (and expressly disclaims any such obligation) to update any forward-looking statements contained in this release as a result of new information or future events or developments, except as may be required by law.

Tables to Follow


  
RCM Technologies, Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In Thousands, Except Share and Per Share Amounts)
 
  
 Thirteen Weeks Ended  
 March 29,
2025
 March 30,
2024
 
Revenue$84,473 $71,939 
Cost of services 62,495  51,572 
Gross profit 21,978  20,367 
Selling, general and administrative 14,971  14,199 
Depreciation and amortization of property and equipment 424  287 
Amortization of acquired intangible assets -  45 
Operating income 6,583  5,836 
Other expense, net 698  426 
Income before income taxes 5,885  5,410 
Income tax expense 1,699  1,458 
Net income$4,186 $3,952 
     
Diluted net earnings per share data$0.54 $0.48 
Diluted weighted average shares outstanding 7,741,481  8,170,839 


RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis
(Unaudited)
(In Thousands, Except Per Share Amounts)

The following non-GAAP measures, which adjust for the categories of expenses described below, are non-GAAP financial measures.  Our management believes that these non-GAAP financial measures (“Adjusted operating income,” “EBITDA,” “Adjusted EBITDA,” “Adjusted net income” and “Adjusted diluted net earnings per share”) are useful information for investors, shareholders, and other stakeholders of our Company in gauging our results of operations on an ongoing basis and to enhance investors’ overall understanding of our current financial performance and period-to-period comparisons.  Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share should not be considered alternatives to operating income or net income, as the case may be, as an indicator of performance.  In addition, Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share do not take into account changes in certain assets and liabilities and interest and income taxes that can affect cash flows.  We do not intend the presentation of these non-GAAP measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP. These non-GAAP measures should be read-only in conjunction with our consolidated financial statements prepared in accordance with GAAP.

The following unaudited table presents the Company’s GAAP operating income and GAAP net income and the corresponding adjustments used to calculate Adjusted operating income, EBITDA, Adjusted EBITDA, Adjusted net income and Adjusted diluted net earnings per share for the thirteen weeks ended March 29, 2025 and March 30, 2024. 

 Thirteen Weeks Ended 
 March 29,
2025
 March 30,
2024
 
 (Unaudited)   
     
GAAP operating income$6,583 $5,836 
Adjustments    
Equity compensation 773  635 
Adjusted operating income (non-GAAP)$7,356 $6,471 
     
GAAP net income$4,186 $3,952 
Income tax expense 1,699  1,458 
Interest expense, net 651  478 
Depreciation of property and equipment 424  287 
Amortization of acquired intangible assets -  45 
EBITDA (non-GAAP)$6,960 $6,220 
     
Adjustments    
Loss (gain) on foreign currency transactions 47  (52)
Equity compensation 773  635 
Adjusted EBITDA (non-GAAP)$7,780 $6,803 


 
RCM Technologies, Inc.
Supplemental Operating Results on a Non-GAAP Basis (Continued)
(Unaudited)
(In Thousands)
 
 Thirteen Weeks Ended 
 March 29,
2025
 March 30,
2024
 
 (Unaudited)   
     
GAAP net income$4,186 $3,952 
Adjustments    
Loss (gain) on foreign currency transactions 47  (52)
Equity compensation 773  635 
Tax impact from normalized rate (111) (160)
Adjusted net income (non-GAAP)$4,895 $4,375 
     
GAAP diluted net earnings per share$0.54 $0.48 
Adjustments    
Loss (gain) on foreign currency transactions 0.01  (0.01)
Equity compensation 0.10  0.08 
Tax impact from normalized rate (0.02) (0.02)
Adjusted diluted net earnings per share (non-GAAP)$0.63 $0.53 


 
RCM Technologies, Inc.
Summary of Selected Income Statement Data
(Unaudited)
(In Thousands)
 
 Thirteen Weeks Ended March 29, 2025 
 Specialty
Health Care
 Engineering Life Sciences,
Data and Solutions
 

Consolidated
 
         
Revenue$43,283 $32,142 $9,048 $84,473 
Cost of services 31,080  25,957  5,458  62,495 
Gross profit$12,203 $6,185 $3,590 $21,978 
Gross profit margin 28.2% 19.2% 39.7% 26.0%


 Thirteen Weeks Ended March 30, 2024 
 Specialty
Health Care
 Engineering Life Sciences,
Data and Solutions
 

Consolidated
 
         
Revenue$38,182 $23,505 $10,252 $71,939 
Cost of services 27,108  18,003  6,461  51,572 
Gross profit$11,074 $5,502 $3,791 $20,367 
Gross profit margin 29.0% 23.4% 37.0% 28.3%


 
RCM Technologies, Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In Thousands, Except Share Amounts)
 
 March 29, December 28, 
 2025 2024 
 (Unaudited)   
Current assets:    
 Cash and cash equivalents$5,181 $4,729 
 Accounts receivable, net of provision for credit losses of $1,570
at March 29, 2025 and December 28, 2024
 68,390  77,960 
 Transit accounts receivable 7,165  7,315 
 Prepaid expenses and other current assets 5,240  7,034 
  Total current assets 85,976  97,038 
       
Property and equipment, net 7,371  7,368 
     
Other assets:    
 Deposits 233  230 
 Deferred tax assets, foreign 125  120 
 Goodwill 22,147  22,147 
 Operating right of use asset 5,140  5,174 
  Total other assets 27,645  27,671 
       
  Total assets$120,992 $132,077 


Current liabilities:    
 Accounts payable and accrued expenses$14,509 $13,369 
 Transit accounts payable 19,327  23,870 
 Accrued payroll and related costs 12,581  9,929 
 Finance lease payable 706  698 
 Income taxes payable 273  346 
 Operating right of use liability 1,107  1,046 
 Contingent consideration from acquisitions 212  212 
 Deferred revenue 4,519  4,163 
  Total current liabilities 53,234  53,633 
     
Deferred income taxes, net, domestic 4,526  4,526 
Finance lease payable, net of current position 932  1,112 
Operating right of use liability, net of current position 4,286  4,355 
Borrowings under line of credit 23,414  34,967 
 Total liabilities 86,392  98,593 
     
Contingencies (note 15)    
     
Stockholders’ equity:    
 Preferred stock, $1.00 par value; 5,000,000 shares authorized;    
  no shares issued or outstanding -  - 
 Common stock, $0.05 par value; 40,000,000 shares authorized;    
  17,928,284 shares issued and 7,508,593 shares outstanding at
March 29, 2025 and 17,838,372 shares issued and 7,602,113 shares
outstanding at December 28, 2024
 895  890 
 Additional paid-in capital 118,956  118,845 
 Accumulated other comprehensive loss (2,918) (2,920)
 Accumulated deficit (1,752) (5,938)
 Treasury stock, 10,419,691 shares at March 29, 2025 and    
  10,236,259 shares at December 28, 2024 (80,581) (77,393)
  Total stockholders’ equity 34,600  33,484 
       
  Total liabilities and stockholders’ equity$120,992 $132,077 


 
RCM Technologies, Inc.
Condensed Consolidated Statements of Cash Flows
(Unaudited)
(In Thousands)
 
 Thirteen Weeks Ended  
 March 29,
2025
 March 30,
2024
 
Net income$4,186 $3,952 
Adjustments to reconcile net income to cash
used in operating activities
 1,459  1,250 
Changes in operating assets and liabilities:    
 Accounts receivable 9,558  (2,802)
 Prepaid expenses and other current assets 1,787  120 
 Net of transit accounts receivable and payable (4,393) (219)
 Accounts payable and accrued expenses 1,358  1,345 
 Accrued payroll and related costs 2,665  976 
 Right of use liabilities (241) (304)
 Income taxes payable (71) 451 
 Deferred revenue 356  1,633 
 Deposits (4) 24 
Total adjustments 12,474  2,474 
Net cash provided by operating activities$16,660 $6,426 
     
Net cash used in investing activities (427) (669)
Net cash used in financing activities (15,583) (9,714)
Effect of exchange rate changes on cash and cash equivalents (198) (228)
Increase (decrease) in cash and cash equivalents$452 ($4,185)
     
Common stock repurchase($3,188) $- 
Retirement of common shares($939)($1,317)


   
RCM Technologies, Inc.Tel: 856.356.4500Corporate Contacts:
2500 McClellan Avenueinfo@rcmt.comBradley S. Vizi
Pennsauken, NJ 08109www.rcmt.comExecutive Chairman
  Kevin D. Miller
  Chief Financial Officer

FAQ

What was RCMT's revenue growth in Q1 2025?

RCMT's revenue grew 17.4% year-over-year to $84.5 million in Q1 2025, compared to $71.9 million in Q1 2024.

How much did RCM Technologies reduce its net debt in Q1 2025?

RCM Technologies reduced its net debt by $12.0 million during Q1 2025 while also retiring shares and growing earnings.

What was RCMT's earnings per share in the first quarter of 2025?

RCMT reported GAAP earnings of $0.54 per diluted share and adjusted earnings of $0.63 per diluted share in Q1 2025.

Which segment generated the highest revenue for RCMT in Q1 2025?

The Specialty Health Care segment generated the highest revenue at $43.3 million, followed by Engineering at $32.1 million.

What was RCM Technologies' operating cash flow in Q1 2025?

RCM Technologies generated $16.7 million in cash flow from operations during Q1 2025.
Rcm Tech

NASDAQ:RCMT

RCMT Rankings

RCMT Latest News

RCMT Stock Data

132.34M
4.85M
33.69%
38.71%
2.01%
Conglomerates
Services-help Supply Services
Link
United States
PENNSAUKEN